Kazuoki Kondo

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

Koji Abe, Masashi Aoki, Shoji Tsuji et al. · The Lancet Neurology · 2017 · 900 citations

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +6

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Koji Abe, Yasuto Itoyama, Gen Sobue et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2014 · 348 citations · Full text

Multiple Factors Contribute to the Pathogenesis of Hypertension in Cushing's Syndrome

Takao Saruta, Hiromichi Suzuki, Michiko Handa et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 204 citations

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study

Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari et al. · Diabetes Obesity and Metabolism · 2013 · 134 citations · Full text

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Nobuya Inagaki, Kazuoki Kondo, Toru Yoshinari et al. · Expert Opinion on Pharmacotherapy · 2014 · 120 citations